Home / Health / Vaginal Swab Replaces Painful Biopsy for Cancer
Vaginal Swab Replaces Painful Biopsy for Cancer
3 Apr
Summary
- A new, painless vaginal swab test offers an alternative to endometrial cancer biopsies.
- Clinical trials are underway at 12 major U.S. medical centers, including Mayo Clinic.
- The test may be available nationwide by mid-2027 for symptomatic women.
A new diagnostic approach for endometrial cancer offers a non-invasive and painless alternative to traditional biopsies. This innovative vaginal swab test, developed by PinkDx, aims to simplify the diagnostic process for women experiencing abnormal bleeding, a common symptom of the disease.
Clinical validation trials are currently underway at 12 prominent medical centers in the U.S., including the Mayo Clinic and Columbia University. The company anticipates that if these studies proceed as planned, the test could become widely available nationwide by mid-2027.
The test involves a simple vaginal swab, with results analyzed by a specialized algorithm within two weeks. A positive result guides further confirmation and treatment, while a negative result allows for the exploration of other potential causes for symptoms, avoiding immediate invasive procedures. This development is particularly significant as endometrial cancer rates are rising, especially among postmenopausal women.
PinkDx emphasizes that the test is intended for women with symptoms, not as a general screening tool for all women. The company is also focused on addressing disparities, with 30% of clinical trial participants being women of color, acknowledging that endometrial cancer disproportionately affects Black women.
